A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac)-labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC).

Category Primary study
JournalJ. Clin. Oncol.
Year 2024
This article has no abstract
Epistemonikos ID: 5a95171f96326abfe9e60542f7e5b767e8f8d841
First added on: Dec 13, 2025